BioDelivery Sciences to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019
30 juil. 2019 07h45 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions,...
BioDelivery Sciences Expands Upon Report from Pain Management Task Force
24 juin 2019 08h00 HE
|
BioDelivery Sciences International, Inc.
Company’s Activities Support Buprenorphine Recommendations Including: Primary Use of Buprenorphine in Chronic Pain when Clinically IndicatedHaving Payers Provide Coverage and Reimbursement for...
BioDelivery Sciences Named to the Russell 3000® Index
20 juin 2019 08h00 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., June 20, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is set to be added to the broad-market Russell 3000® Index as well as the Russell 2000® Index...
BioDelivery Sciences Reports Strong First Quarter 2019 Results and Raises BELBUCA® Full-Year Expectations
06 mai 2019 16h05 HE
|
BioDelivery Sciences International, Inc.
BELBUCA® Net Sales Increased by 134% versus Prior Year to All-time High of $18.7 MillionSymproic® Acquisition and Commercial Integration Successfully CompletedCompany Raises Full-Year BELBUCA Net...
BioDelivery Sciences to Report First Quarter 2019 Financial Results
25 avr. 2019 16h30 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., April 25, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Announces Expanded Preferred Insurance Coverage For BELBUCA®
04 févr. 2019 08h03 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences Appoints Terry Coelho as Chief Financial Officer
15 janv. 2019 07h30 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Jan. 15, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences Reports Strong Third Quarter 2018 Financial Results
08 nov. 2018 16h05 HE
|
BioDelivery Sciences International, Inc.
BELBUCA® continued on an accelerated growth trajectory, with revenue increasing 92% YOY and 27% versus prior quarterBELBUCA total prescriptions experienced its largest quarter over quarter increase...
BioDelivery Sciences Announces Changes to its Executive Leadership Team
29 oct. 2018 08h30 HE
|
BioDelivery Sciences International, Inc.
James Vollins joins the Company in role of General Counsel, Chief Compliance Officer, and Corporate Secretary Ernest De Paolantonio, Chief Financial Officer announces plan to retire by mid-2019 ...
BioDelivery Sciences to Report Third Quarter 2018 Financial Results on November 8, 2018
23 oct. 2018 08h00 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Oct. 23, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...